• Medicus Pharma scheduled new Phase 1 data on Teverelix, investigational long-acting GnRH antagonist, for presentation at AACE 2026 on April 24.
• Poster will cover two completed Phase 1 studies in 48 healthy premenopausal women evaluating single-dose subcutaneous administration.
• Results showed consistent, reversible hormone suppression that supports potential infrequent dosing for hormone-driven conditions such as endometriosis or uterine fibroids.
• Safety readout indicated drug was generally well tolerated, with findings supporting further patient-based studies.
• Medicus plans a genomics-enabled development program in symptomatic endometriosis with Omics Labs in United Arab Emirates to refine patient selection and improve trial efficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150730PRIMZONEFULLFEED9688839) on April 15, 2026, and is solely responsible for the information contained therein.